Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)Original paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how gepotidacin, a first-in-class triazaacenaphthylene antibiotic with a novel mechanism of action, affects the human microbiome during treatment for uncomplicated urinary tract infections. It was conducted as part of a randomised Phase 2a clinical trial evaluating repeated oral doses of gepotidacin (GSK2140944). Researchers tracked microbiota composition across three body sites, the gastrointestinal tract, the pharyngeal cavity, and the vagina, using 16S rRNA gene sequencing. Samples were collected at three time points relative to dosing to capture both immediate effects and later recovery.
Who was studied?
The study population consisted of 22 adult female patients with uncomplicated urinary tract infections who were enrolled in the gepotidacin Phase 2a trial (ClinicalTrials.gov NCT03568942). Each participant contributed microbiome samples from the gut, throat, and vagina. Samples were collected pre-dose on Day 1, at the end of dosing on Day 5, and at a Follow-up visit around Day 28. This design allowed within-subject comparison of microbiome changes over the course of treatment and recovery.
What were the most important findings?
By Day 5, at the end of the gepotidacin dosing regimen, significant changes in microbiome diversity were observed relative to pre-dose baseline across all three tested body sites. These shifts indicate that gepotidacin measurably disrupted the gut, pharyngeal, and vaginal microbiota during active treatment. By the Follow-up visit approximately three weeks later, microbiome diversity had reverted to compositions comparable to Day 1 baseline. This pattern points to disruption during dosing followed by recovery after treatment ended, though the abstract does not specify which body site showed the greatest change.
What are the greatest implications of this study?
The findings suggest that gepotidacin's effects on the microbiome are transient rather than persistent, with diversity returning to baseline within about a month of treatment completion. This supports the value of characterizing microbiome impacts early in antibiotic drug development, especially for agents with novel mechanisms of action. Demonstrating recovery across multiple body sites, not just the gut, offers reassurance about the drug's broader ecological footprint. The approach also illustrates a model for how future antibiotic trials might systematically monitor microbiome perturbation and recovery as part of safety evaluation.